

CURRICULUM VITAE

NAME **Mark C. Kelley, MD, FACS**
Assistant Professor of Surgery
Division of Surgical Oncology

ADDRESS Vanderbilt University Medical Center
597 Preston Building
Nashville, TN 37232-6860

Phone: (615)-343-4586
Fax: (615)-343-4598

PERSONAL HISTORY

DATE OF BIRTH August 17, 1964
BIRTHPLACE Tacoma, Washington USA
HOMETOWN Gainesville, Florida

EDUCATION

COLLEGE University of Florida, Gainesville, Florida
Major: Interdisciplinary Studies 7/82-5/85
Degree: Bachelor of Science (High Honors) 5/23/85

MEDICAL SCHOOL University of Florida, Gainesville, Florida
Program: Medicine 8/85-5/89
Degree: Doctor of Medicine (Honors) 5/27/89

INTERNSHIP & RESIDENCY University of Florida, Gainesville, Florida
General Surgery 7/89-6/95
Surgical Research Resident 7/91-6/92
Chief Resident 7/94-6/95

FELLOWSHIP John Wayne Cancer Institute
Santa Monica, California
Surgical Oncology Fellow 7/95-7/97

LICENSURE

Tennessee Board of Medical Examiners
License Active

Certified 7/97 Expires 8/03

The Medical Board of California
License Inactive
Certified 4/95 Expired 8/97

Florida Board of Medical Examiners
License Inactive
Certified 7/91 Expired 12/95

Drug Enforcement Administration
License Active
Certified 9/91 Expires 12/03

CERTIFICATION

American Board of Surgery
National Board of Medical Examiners
Advanced Cardiac and Trauma Life Support

MEDICAL STAFF APPOINTMENTS

Vanderbilt University Medical Center
Nashville, Tennessee (Active Staff)

Nashville VA Medical Center
Nashville, Tennessee (Active Staff)

ACADEMIC APPOINTMENTS

Vanderbilt University
Nashville, Tennessee
Assistant Professor of Surgery, 7/97-present

John Wayne Cancer Institute
Santa Monica, California
Assistant Member, 7/95-7/97

MEMBERSHIPS

Association for Academic Surgery
American Association for Cancer Research

American College of Surgeons (Fellow, 10/01)
American College of Surgeons Oncology Group
American Society for Clinical Oncology
American Society of Breast Surgeons
Eastern Cooperative Oncology Group
Society for Surgery of the Alimentary Tract
Society of Surgical Oncology
Vanderbilt-Ingram Cancer Center
Edward R. Woodward Society
H. William Scott, Jr. Society
The Nashville Surgical Society

COMMITTEES

Society of Surgical Oncology
Issues and Government Affairs Committee 3/98-3/01

ADMINISTRATIVE DUTIES

Clinical Director, Vanderbilt Breast Center 7/97-present
Director, Vanderbilt Melanoma Program 7/97-12/01
Associate Director, Vanderbilt Melanoma Program 01/02-present
Associate Director, Vanderbilt Clinical Breast Cancer Program 7/97-present
Member, Experimental Therapeutics Program 6/98-present
Chairman, Vanderbilt University Medical Center Cancer Committee 12/00-present
Acting Chief, Division of Surgical Oncology 7/01-09/02
Chief, Division of Surgical Oncology 10/02- present

HONORS AND AWARDS

Phi Beta Kappa (1986)
Alpha Omega Alpha, Junior Class Election (1988)
Robert Donohoe Award in General Surgery (1989)
Florida Obstetric and Gynecologic Society Award (1989)
Walter Oppelt Award for Pharmacology Research (1989)
Outstanding Teaching Resident (1995)
Edward R. Woodward Award (1995)
Surgical Research Award (1992)

TEACHING EXPERIENCE

Vanderbilt University School of Medicine
Division of Surgical Oncology
Assistant Professor of Surgery 1997-Present

University of Southern California
Department of Surgery
Instructor in Surgery 1996

RESEARCH INTERESTS

CLINICAL

Clinical Trials of Molecular Targeted Therapy for Breast Cancer and Melanoma.

Clinical Trials of Neoadjuvant Therapy for Operable Breast Cancer and Melanoma

Clinical Trials of Immunotherapy for Melanoma

Lymphatic Mapping and Sentinel Lymphadenectomy

Evaluation and Management of Women at High Risk of Developing Breast Cancer

BASIC SCIENCE

Molecular and Cellular Biology of Melanoma and Breast Cancer

Tumor Immunology and Immunotherapy

RESEARCH PROTOCOLS

- CLINICAL 1) Sentinel node mapping for breast cancer: a pilot study (VCC BRE-9702). **Principal Investigator**. No extramural funding.
- 2) Early detection of occult micrometastases by lymph node mapping and RT-PCR in patients with invasive breast cancer: A multi-center trial (VCC BRE-9703). **Principal Investigator**. Funded by the Department of Defense (DOD) through Moffitt Cancer Center. (Closed)
- 3) A phase III randomized double-blind trial of immunotherapy with a polyvalent melanoma vaccine (C-VAX) plus BCG versus placebo plus BCG as a post-surgical treatment for stage IV melanoma (VCC MEL-9807). **Principal Investigator**. Funded by the National Cancer Institute (NCI) and CancerVax^R Corporation.
- 4) A phase III randomized double-blind pivotal trial of immunotherapy with BCG plus a polyvalent melanoma vaccine (C-VAX) versus BCG plus placebo as a post-surgical treatment for stage III melanoma (VCC MEL-9838). **Principal Investigator**. Funded by the NCI and CancerVax^R Corporation.
- 5) A multicenter trial of adjuvant interferon alfa-2b for melanoma patients with early lymph node metastasis detected by lymphatic mapping and sentinel lymph node biopsy (IN MEL-9701). **Principal Investigator**. Funded by Schering-Plough Corporation.
- 6) Local excision alone for selected patients with DCIS of the breast (ECOG BRE-E5194). **Co-Investigator**. Funded by the Eastern Cooperative Oncology Group (ECOG).
- 7) Evaluation of lumpectomy, tamoxifen, and irradiation of the breast compared with lumpectomy plus tamoxifen in women 70 years of age or older with breast cancer that is less than or equal to 2 cm in size: A phase III study (ECOG BRE-C9343). **Co-Investigator**. Funded by ECOG. (Closed)
- 8) NSABP Protocol P2: Study of tamoxifen and Raloxifene for the Prevention of Breast Cancer (IN P-9901) **Principal Investigator**. Funded by the National Surgical Adjuvant Breast and Bowel Program (NSABP).

- 9) Sentinel lymph node mapping in vulvar carcinoma (VCC GYN-9921) **Co-Investigator**. No extramural funding. (Closed)
- 10) Identification of intraductal breast pathology in high-risk women: a multicenter trial (IN BRE-9945) **Principal Investigator**. Funded by Pro-Duct Health Corporation. (Closed)
- 11) A pilot study of molecular-based therapy utilizing neoadjuvant paclitaxel and concurrent radiation in stage II/III breast cancer (VCC BRE-9936) **Co-Investigator**. Funded by an American Cancer Society pilot grant to Vanderbilt-Ingram Cancer Center.
- 12) A prognostic study of sentinel node and bone marrow micrometastasis in women with clinical T1 or T2 No Mo breast cancer. (ACoSOG trial Z-10, IN SUR-0043) **Principal Investigator**. Funded by NCI through ACoSOG.
- 13) A randomized trial of axillary node dissection in women with clinical T1 or T2 No Mo breast cancer who have a positive sentinel node. (ACoSOG trial Z-11, IN SUR-0044) **Principal Investigator**. Funded by NCI through ACoSOG.
- 14) Nashville Breast Health Study. **Co-Investigator**. Funded by the NCI (R-01 to Wei Zheng, MD, PhD).
- 15) A prospective follow-up study evaluating ductal lavage cytology in women at high risk of developing breast cancer. **Principal Investigator**. (closed).
- 16) HER (erbB) tyrosine kinase inhibitors in treatment-naïve operable breast cancer. **Co-Principal Investigator**. Funding application pending to the NCI (SPORE in breast cancer application, Vanderbilt-Ingram Cancer Center).
- 17) A phase I/II clinical trial of PS-341, a proteasome inhibitor in combination with an extended continuous oral schedule of temozolamide in patients with advanced stage melanoma. **Co-Investigator**. Funding application pending to the NCI (R-21 to Dr. Jeffrey Sosman)

BASIC

1) The role of NF- κ B dysregulation in melanoma tumor progression. **Collaborator.** Funded by the NCI (R-01 to Ann Richmond, PhD).

2) Preclinical evaluation of autologous dendritic cells loaded with tumor-derived apoptotic bodies for immunotherapy of melanoma. **Principal Investigator.** Funded by the American Cancer Society Institutional Research Grant to Vanderbilt-Ingram Cancer Center (IRG-58-009-42) and the NIH through the Vanderbilt Physician Scientist Development Program, 01/00-12/00.

3) Evaluation of in vitro anti-tumor immune responses to human dendritic cells loaded with apoptotic melanoma cells. **Principal Investigator.** Funded by the NIH through the Vanderbilt Physician Scientist Development Program. Pilot project funding application to the Vanderbilt-Ingram Cancer Center NCI Cancer Center Support Grant (2P30 CA68485-06) pending.

BIBLIOGRAPHY

Manuscripts

1. O'Malley CA, Hautamaki RD, **Kelley MC**, Meyer EM. Effects of ovariectomy and estradiol benzoate on high affinity choline uptake, acetylcholine synthesis and release from rat cerebral cortical synaptosomes. Brain Research 403:389-392, 1987.
2. **Kelley MC**, Raizada MK, Meyer EM. Pharmacological characterization of high affinity choline transporters in primary neuronal cultures in rat brain. Neuropharmacology 27(8): 837-842, 1988.
3. **Kelley MC**, Hocking MP, Marchand SD, Sninsky CA. Ketorolac prevents postoperative small intestinal ileus in rats. American Journal of Surgery 165(1): 107-112, 1993.
4. Espat NJ, Cheng G, **Kelley MC**, Vogel SB, Sninsky CA, Hocking MP. Vasoactive intestinal peptide and substance P receptor antagonists improve postoperative ileus. Journal of Surgical Research 68(6): 719-723, 1995.
5. Jones RC, **Kelley MC**, Gupta RK, Nizze JA, Yee R, Leopoldo Z, Qi K, Stern S, Morton DL. Immune response to polyvalent melanoma cell vaccine in AJCC stage III melanoma: An immunologic survival model. Annals of Surgical Oncology 3(5): 437-445, 1996.
6. Ravindranath MH, Bauer PM, Amiri AA, Miri SM, **Kelley MC**, Morton DL. Cellular cancer vaccine induces delayed-type hypersensitivity reaction and augments antibody response to tumor-associated carbohydrate antigens better than soluble lysate cancer vaccine. Anti-Cancer Drugs 8: 217-224, 1997.
7. Ravindranath MH, Amiri AA, Bauer PM, **Kelley MC**, Essner R, Morton DL. Endothelial-selectin ligands sialyl-Lewis^x and sialyl-Lewis^a are differentiation antigens immunogenic in human melanoma. Cancer 79: 1686-1697, 1997.
8. Conforti AM, Ollila DW, **Kelley MC**, Morton DL. Update on active specific immunotherapy with melanoma vaccines. Journal of Surgical Oncology 66:55-64, 1997.
9. Bostick P, Essner R, Sarantou T, **Kelley MC**, Glass E, Foshag LJ, Stern S, Morton DL. Intraoperative lymphatic mapping for early-stage melanoma of

- the head and neck. American Journal of Surgery. 174:536-539, 1997.
10. Ravindranath MH, **Kelley MC**, Jones RC, Amiri AA, Bauer PM, Morton DL. Ratio of IgG:IgM antibodies to Sialyl-Lewis^x and GM₃ correlates with tumor growth after immunization with melanoma cell vaccine with different adjuvants. International Journal of Cancer 75:117-24, 1998.
 11. **Kelley MC**, Jones RC, Gupta R, Wanek L, Morton DL. Tumor-associated antigen TA-90 immune complex assay detects occult metastases in early-stage melanoma. Cancer 83(7): 1355-61, 1998.
 12. Ollila DW, **Kelley MC**, Gammon G, Morton DL. Overview of melanoma vaccines: active specific immunotherapy for melanoma patients. Seminars in Surgical Oncology 14:328-336, 1998.
 13. **Kelley MC**, Ollila DW, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for melanoma. Seminars in Surgical Oncology, 14:283-90, 1998.
 14. **Kelley MC**, Giuliano AE. "Lymphatic mapping and sentinel lymphadenectomy for breast cancer" in The Breast: Comprehensive Management of Benign and Malignant Diseases. 2nd Ed. KI Bland and EM Copeland III, Eds. W.B. Saunders, pp 1100-1111, 1998.
 15. Bostick P, Essner R, Glass E, **Kelley MC**, Foshag LJ, Morton DL. Comparison of blue dye and probe-assisted intraoperative lymphatic mapping in melanoma to identify sentinel nodes in 100 lymphatic basins. Annals of Surgery 134(1):43-9, 1999.
 16. Essner, R Conforti A, **Kelley MC**, Foshag LJ, Stern S, Morton DL. Efficacy of lymphatic mapping, sentinel lymphadenectomy, and selective complete lymph node dissection as a therapeutic procedure for early-stage melanoma. Annals of Surgical Oncology 6(5):442-9, 1999.
 17. Giuliano AE, Haigh PI, Brennan MB, Hansen NM, **Kelley MC**, Ye W, Glass E, Turner RR. Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer. Journal of Clinical Oncology 18(13):2553-9, 2000.
 18. Chakravarthy A, Nicholson B, **Kelley MC**, Beauchamp RD, Johnson D, Frexes-Steed M, Simpson J, Shyr Y, Pietenpol J. A pilot study of neoadjuvant paclitaxel and radiation with correlative molecular studies in stage II/III breast cancer. Clinical Breast Cancer 1(1):68-20, 2000.

19. Scoggins CR, **Kelley MC**. Current surgical therapy of rectal cancer. Colorectal Cancer: Index and Reviews 1(4):1-6, 2000.
20. **Kelley MC**, Hsueh E, Jones RC, Gupta RK, Yee R, Stern S, Morton DL. Tumor-associated antigen TA-90 immune complex assay predicts recurrence and survival after surgical resection of stage I-III melanoma. Journal of Clinical Oncology 19(4):1176-82, 2001.
21. Dupont EL, Kamath VJ, Ramnath EM, **Kelley MC**,. et al. The role of lymphoscintigraphy in the management of the patient with breast cancer. Annals of Surgical Oncology 8(4):354-360, 2001
22. Dooley WC, Lyung BM, Veronesi U, Cazzaniga M, Elledge RM, O'Shaughnessy JA, Kuerer HM, Hung DT, Khan SA, Phillips RA, Ganz PA, Euhus DM, Esserman LJ, Haffty BG, King BL, **Kelley MC**, Anderson MM, Schmit PJ, Clark RR, Kass FC, Anderson BO, Troyan SL, Arias RD, Quiring JN, Love SM, Page DL, King EB. Ductal lavage for detection of cellular atypia in women at high risk of breast cancer. Journal of the National Cancer Institute 93(21):1624-1632, 2001.
23. Balch GC, Mithani SK, Richards K, Beauchamp RD, **Kelley MC**. Prospective evaluation of lymphatic mapping and sentinel lymphadenectomy after preoperative therapy for stage II and III breast cancer. Annals of Surgical Oncology, in press.

BIBLIOGRAPHY

Abstracts and Poster Presentations

1. **Kelley MC**, Koppenaal D, Raizada MK, Meyer EM. Pharmacology and Turnover of High Affinity Choline Uptake and Acetylation in Primary Brain Cell Cultures. Presented at the Society of Neuroscience, 1986.
2. **Kelley MC**, Marchand SD, Hocking MP, Sninsky CA. Ketorolac Improves Small Bowel Transit in Rats with Postoperative Ileus. Presented at the 34th Annual University Surgical Resident Conference, Society of University Surgeons, 1992.
3. **Kelley MC**, Langham Jr MR, Hocking MP. Methemoglobinemia is Induced by Endotoxin Through a Nitric Oxide Dependent Pathway. Presented at the American Academy of Pediatrics, Section on Surgery, 1993.
4. Jones RC, **Kelley MC**, Gupta R, Nizze JA, Yee R, Leopoldo Z, Morton DL. Response to Melanoma Cell Vaccine in AJCC Stage III Melanoma: An Immunologic Survival Model. Presented at the Society of Surgical Oncology, 1996.
5. **Kelley MC**, Jones RC, Gupta R, Wanek L, Morton DL. Tumor-Associated Antigen TA-90 Predicts Recurrence, Lymph Node Status and Survival in Stage I and II Melanoma. Presented at the Society of Surgical Oncology, 1996.
6. Jones RC, **Kelley MC**, Gupta R, Morton DL. IgG Subclass Response to Melanoma Cell Vaccine: The Gamma-4 Connection. Proc Am Assoc Cancer Research 37:477, 1996.
7. Gupta R, Nizze JA, Yee R, **Kelley MC**, Leopoldo Z, Stiles A, Dickey A, O'Neill K, Halpin A, Morton DL. Prospective Evaluation of a 90 kD Glycoprotein Tumor-Associated Antigen in Melanoma Patients. Proc Am Soc Clin Oncol 15:93, 1996.
8. Gupta RK, Giuliano AE, **Kelley MC**, Yee R, Leopoldo Z, Morton DL. Clinical Significance of 90 kD Tumor-Associated Antigen-Specific Immune Complexes in Breast Cancer Patients. J Tumor Marker Oncology 11:44, 1996.
9. Essner R, **Kelley MC**, Foshag LJ, Cochran A, Wen D-R, Stern S, Wanek LA,

- Conforti A, Morton DL. Intraoperative Lymphatic Mapping and Selective Lymphadenectomy in 481 Patients with Early-Stage Melanoma. Presented at the American College of Surgeons, 1996.
10. Essner R, Nguyen TX, **Kelley MC**, Hoon DSB. Human Gastrointestinal Carcinomas Respond to Interleukin-4 Through a Functional Interleukin-2 Receptor Gamma Chain. Presented at the Society of Surgical Oncology, 1997.
 11. **Kelley MC**, Nguyen TX, Hoon DSB, Essner R. Regulation of Hepatocyte Growth Factor-Induced Cell Cycle Progression in Pancreatic Carcinoma. Presented at the Society of Surgical Oncology, 1997.
 12. Ravindranath MH, Amiri AA, **Kelley MC**, Jones RC, Morton DL. Tumor Progression After Immunotherapy With Melanoma Cell Vaccine is Predicted by the Ratio of IgG to IgM Antibodies to Sialyl-Lewis^x and GM₃ in a Murine Model. Proc Am Assoc Cancer Res. 38:398, 1997.
 13. Essner R, Nguyen TX, **Kelley MC**, Hoon DSB. Molecular Role of the Interleukin-2 Receptor Common Gamma Chain Subunit (IL-2R γ c) in Controlling Cell Cycle Progression of Human Non-Small Cell Lung Carcinomas by Interleukin-4. Proc Am Assoc Cancer Res. 38:554, 1997.
 14. Essner R, Conforti A, **Kelley MC**, Wanek L, Morton DL. Cost Effective Management of the Inguinal Nodes in Early-Stage Melanoma. Melanoma Res 7(Suppl 1):529, 1997.
 15. **Kelley MC**, Bostick P, Bilchik A, Foshag LJ, Essner R, Kuo C, Conrad A, Boasberg PD, Hoon DSB. Molecular Detection of Pancreatic Carcinoma (PC) with a Multiple-Marker RT-PCR Assay. Proc Am Soc Clin Oncol 16:293a, 1997.
 16. Bostick P, Sarantou T, Essner R, **Kelley MC**, Glass E, Foshag LJ, Morton DL. Intraoperative Lymphatic Mapping for Early-Stage Melanoma of the Head and Neck. Presented at The Society of Head and Neck Surgeons, 1997.
 17. **Kelley MC**, Nguyen TX, Hoon DSB, Essner R. Human Pancreatic Carcinoma Growth and Invasion is Regulated by c-met and Interleukin-4 Receptor Gene Expression. Presented at The Society for Surgery of the Alimentary Tract, 1997.
 18. Essner R, Conforti A, **Kelley MC**, Wanek L, Stern S, Morton DL. Efficacy of selective lymphadenectomy as a therapeutic procedure for early-stage

- melanoma. Presented at The Society of Surgical Oncology, 1998.
19. **Kelley MC**, Leach SD, Simpson JW, Page DL, Beauchamp RD. Routine Review of Histopathology Affects Surgical Management of Melanoma. Presented at the Association for Academic Surgery, 1998.
 20. Roberts JR, Leach SD, **Kelley MC**, Tarpley JL, Sharp K, Beauchamp RD. Transthoracic esophagectomy increases life-threatening complications and length of stay compared to transhiatal esophagectomy. Presented at the Society of Thoracic Surgery, 1999.
 21. Ollila DW, **Kelley MC**, Hansen N, Giuliano AE. Independent experience of SSO fellowship trained surgical oncologists with lymphatic mapping for breast cancer. Presented at The Society of Surgical Oncology, 1999.
 22. Roberts JR, Leach SD, **Kelley MC**, Tarpley JL, Sharp K, Beauchamp RD. Multidisciplinary surgical management and low-dose neoadjuvant radiotherapy decrease operative morbidity and mortality after esophagectomy. Proc Am Soc Clin Oncol 19:290a, 2000.
 23. Donovan J, Roberts JR, Beauchamp RD, Berlin J, Chakravarthy A, **Kelley MC**, Pearson AS. Changing patterns of metastasis following complete response to neoadjuvant therapy in patients with adenocarcinoma of the gastroesophageal junction. Presented at the International Gastric Cancer Congress, 2001.
 24. Balch GC, Mithani SK, Richards K, Beauchamp RD, **Kelley MC**. Prospective evaluation of the accuracy of lymphatic mapping and sentinel lymphadenectomy after preoperative therapy for locally advanced breast cancer. Presented at the Society of Surgical Oncology, 2002.
 25. **Kelley MC**, Knobel SM, Carbone DP. Dendritic cells loaded with apoptotic melanoma cells slow tumor growth and improve survival in a murine immunotherapy model. Presented at the Society of Surgical Oncology, 2002.
 26. Chakravarthy A, **Kelley MC**, Johnson D, Stewart Z, Beauchamp RD, Pearson AS, Stein R, Young R, Simpson J, Shyr Y, Pietenpol JA. Neoadjuvant paclitaxel and radiation for stage II/III breast cancer with correlative molecular markers. Presented at the American Society of Clinical Oncology, 2002.
 27. Gupta RK, Hsueh EC, **Kelley MC**, Morton DL. TA-90 Immune complexes: a new tumor marker for the early detection of sub-clinical metastatic melanoma. Presented at the American Association of Cancer Research, 2002.

INVITED LECTURES

1. University of Florida, Gainesville, FL. Surgery Grand Rounds. "Recent Advances in the Management of Melanoma". March 1996.
2. Arkansas Cancer Research Center, Little Rock, AK. Surgery Grand Rounds. "Recent Advances in the Management of Melanoma". February 1997.
3. Vanderbilt University Medical Center, Nashville, TN. Obstetrics and Gynecology Grand Rounds. "Evaluation and Management of Benign Breast Disease". October 1, 1997.
4. American Cancer Society Breast Cancer Forum, Nashville, TN. "Patient Choices: Surgical Treatment Options for Breast Cancer". October 18, 1997.
5. Vanderbilt University Medical Center, Nashville, TN. Surgery Grand Rounds. "Lymphatic Mapping and Sentinel Lymphadenectomy for Breast Cancer". November 1, 1997.
6. Bedford County Medical Center, Shelbyville, TN. "Recent Advances in the Management of Breast Cancer". November 6, 1997.
7. Vanderbilt University Medical Center, Nashville, TN. Medical Oncology Grand Rounds. "Surgical Management of Primary Breast Cancer" February 3, 1998.
8. Vanderbilt University Medical Center, Nashville, TN. Dermatology Grand Rounds. "Immunotherapy for Melanoma". February 12, 1998.
9. East Tennessee State University, Johnson City, TN. Surgery Grand Rounds. "Lymphatic Mapping and Sentinel Lymphadenectomy for Breast Cancer". March 14, 1998.
10. Tumor Registrar's Association of Tennessee Annual Meeting. Nashville, TN. "Current Management of Breast Cancer". March 20, 1998.
11. Clarksville Memorial Hospital, Clarksville, TN. "Recent Advances in the Surgical Management of Breast Cancer". July 17, 1998.
12. Maury Regional Hospital, Columbia, TN. "Recent Advances in the Management of Breast Cancer". October 15, 1998.
13. Vanderbilt University Medical Center, Nashville, TN. Department of Obstetrics and Gynecology Grand Rounds. "Recent Advances in the Management of Breast Cancer". February 17, 1999.

14. Vanderbilt University Medical Center, Nashville, TN. 1999 Lonnie S. Burnett Vanderbilt OB-GYN Society Meeting. "Tamoxifen and other SERMs for the Prevention of Breast Cancer". June 4, 1999.
15. The Genesys Hurley Cancer Institute, Hurley Medical Center, Flint, MI. Controversies in the Multi Modality Treatment of Breast Cancer. "Current Trends in the Surgical Management of Breast Cancer". October 13, 1999.
16. Cookeville Regional Cancer Center, Cookeville, TN. "Recent Advances in the Surgical Management of Breast Cancer". October 14, 1999.
17. Vanderbilt Department of Radiology, Nashville, TN. "Recent Advances in the Surgical Management of Breast Cancer". October 23, 1999.
18. Vanderbilt University Club, Nashville, TN. Women's Health Conference. Sponsored by Wyeth-Ayerst Labs, AstraZeneca Pharmaceuticals, and UnitedHealthcare. "Recent Advances in the Detection, Treatment, and Prevention of Breast Cancer. November 20, 1999.
19. Vanderbilt University School of Medicine, Nashville, TN. High-Risk Obstetrics Seminar. Specialty Workshop: "Breast Cancer". December 3, 1999.
20. Bedford County Medical Center, Shelbyville, TN. "Breast Cancer Risk Evaluation and Management". January 6, 2000.
21. Vanderbilt-Ingram Cancer Center Affiliate Network, Nashville TN. "Clinical Trials for Women at High Risk of Developing Breast Cancer". March 4, 2000.
22. Cumberland Regional Medical Center, Crossville, TN. "Recent Advances in the Management of Breast Cancer". May 2, 2000.
23. Bedford County Medical Center, Shelbyville, TN. "Recent Advances in the Management of Melanoma". June 22, 2000.
24. Heartland Medical Center, Elizabethtown KY. "Recent Advances in the Management of Melanoma". August 19, 2000.
25. Harton Regional Medical Center, Tullahoma, TN. "Breast Cancer Risk Evaluation and Management". September 14, 2000.
26. Maury Regional Hospital, Columbia, TN. "Breast Cancer Risk Evaluation and Management". October 12, 2000.

27. Susan B. Komen Foundation Breast Cancer Symposium, Nashville, TN. "Breast Cancer Diagnosis and Surgical Treatment". March 31, 2001.
28. Vanderbilt University Medical Center Division of Ambulatory Medicine, Nashville, TN. "Evaluation of Common Breast Complaints". October 5, 2001.
29. Vanderbilt University Medical Center, Nashville, TN. Department of Obstetrics and Gynecology Grand Rounds. "Update on the Management of Melanoma". December 5, 2001.
30. Vanderbilt University Medical Center, Nashville, TN. Department of Surgery Grand Rounds. "Prophylactic mastectomy: Indications, Risks, Benefits" January 18th, 2002.
31. Vanderbilt University Medical Center, Nashville TN. Cancer Genetics Symposium "Breast Cancer Risk Reduction Strategies" January 19th, 2002.
32. The University of Florida, Gainesville FL. Edward M. Copeland III Scientific Symposium. "New Approaches to Immunotherapy of Melanoma" March 1st, 2002.
33. Vanderbilt University Medical Center, Nashville, TN. Department of Surgery Grand Rounds. "Immunotherapy of melanoma: From Bench to Bedside and Back Again" September 13th, 2002.
- 34.